Advertisement

Topics

BrainStorm Cell Therapeutics, Inc. Company Profile

18:52 EDT 19th March 2019 | BioPortfolio

BrainStorm Cell Therapeutics Inc. is a promising company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. For more information, visit the company’s website at www.brainstorm-cell.com.


News Articles [2502 Associated News Articles listed on BioPortfolio]

BrainStorm gets FDA okay for stem cell trial in MS patients

BrainStorm Cell Therapeutics Inc has received approval from the U.S. Food and Drug Administration to begin a clinical trial of its experimental stem cell treatment in patients with progressive multip...

BrainStorm submits IND for progressive multiple sclerosis drug trial

BrainStorm Cell Therapeutics submitted to the FDA an investigational new drug application seeking approval for a midstage stu -More- 

FDA Accepts BrainStorm’s NurOwn IND Application for Progressive Multiple Sclerosis

BrainStorm Cell Therapeutics (NASDAQ:BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, announced that the U.S. Food and Dru...

BrainStorm Cell Therapeutics to Present at the 29th International Symposium on ALS/MND

NEW YORK, Dec. 04, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegener...

BrainStorm Cell Therapeutics to Present at November Clinical and Investor Conferences

Highlights Preclinical Research and Continued Progress of NurOwn® Platform in ALS Pivotal Trial NEW YORK and PETACH TIKVAH, Israel, Nov. 07, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeuti...

Brainstorm Cell Therapeutics (BCLI) Presents At BIO CEO & Investor Conference - Slideshow

BrainStorm Granted Additional Patent for NurOwn in Israel

BrainStorm Cell Therapeutics (NASDAQ:BCLI), a leader in developing innovative autologous cellular therapies for debilitating neurodegenerative diseases, today announced that the Israel Patent Office h...

BrainStorm Cell Therapeutics Announces Submission of IND for NurOwn® in Progressive Multiple Sclerosis

NEW YORK, Nov. 19, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegener...

Drugs and Medications [30 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [kastle therapeutics, llc]

NA

Olopatadine hydrochloride [somerset therapeutics, llc]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Olopatadine hydrochloride [a-s medication solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Folotyn [allos therapeutics]

These highlights do not include all the information needed to use FOLOTYN safely and effectively. See full prescribing information for FOLOTYN.FOLOTYN (pralatrexate injection), for intravenous use Ini...

Oxygen [breathe easy therapeutics, inc]

NA

PubMed Articles [3299 Associated PubMed Articles listed on BioPortfolio]

Assessing the Effects of Ripasudil, a Novel Rho Kinase Inhibitor, on Human Corneal Endothelial Cell Health.

To determine how the Rho kinase inhibitor, ripasudil, affects metabolic function and cell viability in donor human corneal endothelial cells (HCECs).

RNA-Targeted Therapeutics.

A Delicate Balance - The BCL-2 Family and its Role in Apoptosis, Oncogenesis, and Cancer Therapeutics.

Evasion of apoptosis is fundamental to the pathogenesis of cancer. Members of the B-cell Lymphoma 2 (BCL-2) protein family are key pro- and anti-apoptotic regulators, and in healthy cells are held in ...

Curing cancer by cancer function.

Cancer is the disease which exists when the cell is uncontrolled. This paper presents a controller for the same. The cancer cell is reviewed via algebraic structures.

The use of fast photochemical oxidation of proteins coupled with mass spectrometry in protein therapeutics discovery and development.

Structural analysis of protein therapeutics is a challenging task owing to complexities associated with large molecular size and 3D structures. Recent advances in fast photochemical oxidation of prote...

Clinical Trials [6910 Associated Clinical Trials listed on BioPortfolio]

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

Autologous Unselected Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease

This study evaluates the safety and clinical benefits of a therapeutics approach of conditioning regimen Cyclophosphamide (Cy) + Thymoglobulin r (ATG) + Granulocyte Colony-Stimulating Fact...

Companies [2230 Associated Companies listed on BioPortfolio]

BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a promising company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of ne...

Brainstorm Cell Therapeutics

BrainStorm (OTC BB: BCLI) is a company that is developing stem cell technologies to provide treatments for currently incurable neurodegenerative diseases. The Company is focused on developing adult st...

BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is an emerging company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of ne...

Magenta Therapeutics

Magenta Therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based dise...

Opsis Therapeutics

Opsis Therapeutics is a company focused on discovering and developing new medicines to restore vision to patients suffering from retinal diseases. By combining recent innovations ...

More Information about "BrainStorm Cell Therapeutics, Inc." on BioPortfolio

We have published hundreds of BrainStorm Cell Therapeutics, Inc. news stories on BioPortfolio along with dozens of BrainStorm Cell Therapeutics, Inc. Clinical Trials and PubMed Articles about BrainStorm Cell Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BrainStorm Cell Therapeutics, Inc. Companies in our database. You can also find out about relevant BrainStorm Cell Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...


Corporate Database Quicklinks



Searches Linking to this Company Record